Immunotherapy Side Effects: What Patients Should Actually Expect

Cancer immunotherapy works by unleashing the immune system against tumors, and that same mechanism is why it produces a distinct side effect profile from chemotherapy or radiation. This article walks through what's actually known about the two dominant immunotherapy categories — immune checkpoint inhibitors and CAR-T cell therapy — including real incidence rates, how severity is graded, how oncology teams manage flare-ups, and a genuinely significant 2025 regulatory change that eased the monitoring burden for CAR-T patients without loosening the underlying safety net.

Why Immunotherapy Side Effects Are Different

Chemotherapy toxicity comes from killing fast-dividing cells indiscriminately. Immunotherapy toxicity comes from something almost the opposite: an immune system that has been deliberately released from its normal brakes. Checkpoint inhibitors block proteins like PD-1, PD-L1, and CTLA-4 that tumors exploit to evade immune attack — but those same checkpoints normally protect healthy tissue from autoimmune attack too. When they're blocked, T cells can turn on the gut, lungs, liver, skin, and hormone-producing glands. CAR-T cell therapy takes a patient's own T cells, engineers them to recognize a cancer antigen, and reinfuses billions of them — and the resulting immune activation can be explosive in the days after infusion. Understanding these two distinct toxicity patterns is the foundation for knowing what to actually watch for.

Checkpoint Inhibitors: Immune-Related Adverse Events (irAEs)

Immune-related adverse events are common, not rare exceptions. Across trials, CTLA-4 inhibitors (like ipilimumab) trigger irAEs of some grade in roughly 90% of patients, while PD-1/PD-L1 inhibitors (like pembrolizumab or nivolumab) cause them in about 70%. Severe (grade 3/4) reactions occur in roughly 21% of patients on average, though rates vary widely by drug and combination. Combining a CTLA-4 drug with a PD-1/PD-L1 drug substantially raises both the frequency and severity of side effects compared with either drug alone. The organ systems most often affected, with approximate rates: gastrointestinal toxicity (PD-1 monotherapy causes diarrhea in about 12–14% and colitis in under 2%; CTLA-4 therapy causes diarrhea in 27–54% and colitis in 8–22%); liver toxicity (about 2–10% with monotherapy, rising to 25–30%, with roughly 15% grade 3, when ipilimumab and nivolumab are combined); lung toxicity, or pneumonitis (around 4–5% overall for any-grade pneumonitis with monotherapy, roughly doubling to near 10% with CTLA-4/PD-1 combinations — most cases are mild to moderate, but severe or fatal pneumonitis does occur, with fatal cases estimated at about 0.4% on monotherapy and 1.2% on combination therapy); endocrine dysfunction such as thyroiditis (roughly 10% overall, with hypothyroidism affecting 6–9% on PD-1 monotherapy and around 16% on combination therapy, and unlike most other irAEs, endocrine dysfunction is frequently permanent and typically managed with lifelong hormone replacement rather than immune suppression); and skin toxicity (the most common irAE, affecting roughly 34–42% on CTLA-4, 44–59% on PD-1, and 59–72% on combination therapy — usually mild, but sometimes requiring treatment interruption).

How irAEs Are Managed

Management follows established, ASCO-published guidelines and generally scales with severity grade (graded 1 through 4, similar to standard oncology toxicity grading). Mild (grade 1) reactions are often monitored without stopping treatment. Moderate (grade 2) reactions typically prompt a treatment pause and a course of corticosteroids. Severe (grade 3/4) reactions usually require hospitalization, high-dose steroids, and permanent discontinuation of the checkpoint inhibitor; steroid-refractory cases may need additional immunosuppressants such as infliximab (for colitis) or mycophenolate. The key practical point for patients: irAEs can emerge weeks to months after treatment starts — and even after treatment ends — so any new, persistent symptom (unusual fatigue, bowel changes, breathlessness, rash, or symptoms of thyroid dysfunction) should be reported promptly rather than dismissed as unrelated.

CAR-T Cell Therapy: CRS and ICANS

CAR-T's signature toxicities are cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS), both graded using the ASTCT consensus criteria published in 2019. CRS results from the massive cytokine surge as infused T cells activate and expand; in pooled data it affects roughly two-thirds of patients (about 67% any grade), with severe grade 3 CRS in about 10% and grade 4 in about 3%. Onset is typically fast — a median of around three days post-infusion — which is exactly why CAR-T patients are closely observed in the days immediately following treatment. ICANS, a neurologic toxicity involving confusion, word-finding difficulty, tremor, or in severe cases seizures and cerebral edema, is also common: meta-analyses put all-grade incidence around 27–65% depending on the study population, with high-grade (severe) ICANS in roughly 10% of patients overall. Risk varies meaningfully by product — axicabtagene ciloleucel has shown higher neurotoxicity rates (around 42% any-grade, 20–28% high-grade) than tisagenlecleucel (around 16–20% any-grade, 4–10% high-grade), likely related to differences in the CAR's costimulatory domain. The reassuring counterpart to these numbers: both toxicities are now well-understood and manageable in experienced centers. Tocilizumab, an IL-6 receptor blocker, is the frontline treatment for CRS and produces rapid improvement in most patients; corticosteroids are added for more severe or steroid-responsive cases, and for ICANS in particular.

A Genuine Step Forward: FDA Eases CAR-T Monitoring Requirements

In a development worth featuring on its own merits, the FDA eliminated the Risk Evaluation and Mitigation Strategy (REMS) programs for all six approved autologous CAR-T therapies — Abecma, Breyanzi, Carvykti, Kymriah, Tecartus, and Yescarta — effective June 2025. This wasn't a loosening of safety standards for its own sake; the agency explained that after years of real-world use, the hematology-oncology community had built enough collective expertise managing CRS and neurotoxicity, and adverse-event reporting had remained stable enough, that a dedicated REMS program was no longer necessary to ensure the benefits of these therapies continued to outweigh their risks. The practical impact for patients is substantial: previously, REMS required patients to remain within proximity of a certified treatment center for weeks after infusion and refrain from driving for an extended period, and treatment was restricted to a limited number of specially certified centers nationwide — a real burden for patients who had to relocate or travel long distances for weeks. Under the revised labeling, the required observation period near a treatment facility has been shortened, driving restrictions have been eased, and eligible community cancer centers can now offer CAR-T without the prior certification process, expanding geographic access — particularly meaningful for rural patients. Importantly, this is not a reduction in actual safety obligations: boxed warnings for CRS and neurotoxicity remain on product labels, manufacturers must continue mandatory adverse-event reporting, and long-term follow-up safety studies remain a federal requirement. The monitoring burden eased because the underlying safety data supported it — not because the risks themselves became smaller.

What This Means in Practice

None of this makes checkpoint inhibitors or CAR-T therapy risk-free, and no credible source suggests otherwise. Severe, hospitalization-requiring toxicity is a real possibility with both modalities, and some effects — notably certain endocrinopathies — can be lifelong. But the field has also matured considerably: grading systems are now standardized, specific antidotes exist (tocilizumab for CRS, steroids and targeted immunosuppressants for irAEs), and regulatory bodies are recalibrating monitoring requirements as real-world data accumulates. The right frame for a patient isn't "safe" versus "dangerous" — it's understanding which specific toxicities apply to which specific therapy, how they're graded, and what the monitoring plan looks like at the treating center.

Bottom Line

Ask your oncology team three concrete questions before starting either therapy: What is the expected incidence and severity of side effects specific to this exact drug or CAR-T product (not a generic average)? What is the institution's protocol for grading and escalating a reaction — including who to call and how fast — if symptoms appear at home? And, for CAR-T specifically, what does the post-infusion monitoring plan actually require given the 2025 REMS changes (how many days of observation, how far you need to stay from the treatment center, when you can drive again)? A center that can answer these precisely, rather than in generalities, is one that treats side-effect management as seriously as the treatment itself.